Isofluran Piramal

Isoflurane, the active ingredient in Isofluran Piramal, is an inhalational anesthetic presented as a sterile solution for inhalation use. It produces rapid loss of consciousness and analgesia, allowing both induction and maintenance of general anesthesia in adult and pediatric surgical patients.

GNH USA supplies Isofluran Piramal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Isoflurane is used in the anesthetic pathway to provide controlled loss of consciousness during surgery.

- Induction of general anesthesia: provides rapid onset of unconsciousness for surgical procedures. - Maintenance of general anesthesia: sustains appropriate depth of anesthesia throughout the operative period. - Pediatric anesthesia: enables safe anesthesia management in children undergoing surgery. - Outpatient procedures: facilitates short‑duration anesthesia for minor surgeries.

Isoflurane may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Airway irritation: cough or laryngospasm. - Hypotension: reduced blood pressure. - Respiratory depression: decreased ventilation.

Serious or Rare Side Effects: - Malignant hyperthermia: rare life‑threatening hypermetabolic reaction. - Cardiac arrhythmia: severe rhythm disturbances. - Hepatic dysfunction: rare liver enzyme elevation.

When using Isofluran Piramal, clinicians should observe several safety measures.

- Patient monitoring: continuous ECG, blood pressure, and oxygen saturation. - Ventilation management: adjust fresh gas flow and tidal volume as needed. - Temperature control: maintain normothermia to reduce risk of malignant hyperthermia. - Drug interactions: avoid concurrent use with potent CYP450 inhibitors without monitoring. - Special populations: use cautiously in patients with cardiovascular disease. - Store at ambient temperature: keep container sealed, protect from light and moisture.

Isofluran Piramal can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Potent CYP2E1 inhibitors: may increase Isoflurane plasma levels. - Central nervous system depressants (e.g., high‑dose opioids): risk of profound respiratory depression. - Sodium channel blockers (e.g., certain antiarrhythmics): may exacerbate cardiac depression.

Moderate Interactions (Monitor Closely): - Co‑administration with other halogenated anesthetics: additive CNS depression. - Beta‑blockers: may enhance hypotensive effect. - Diuretics: may affect renal clearance of metabolites.